CRDF Cardiff Oncology Inc

Price (delayed)

$8

Market cap

$300.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.92

Enterprise value

$286.4M

Highlights
Cardiff Oncology's EPS has surged by 59% YoY and by 15% QoQ
Cardiff Oncology's debt has shrunk by 58% YoY and by 26% QoQ
The net income has declined by 23% year-on-year and by 6% since the previous quarter
The equity has declined by 2.6% since the previous quarter

Key stats

What are the main financial stats of CRDF
Market
Shares outstanding
37.55M
Market cap
$300.42M
Enterprise value
$286.4M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.37
Price to sales (P/S)
802.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
773.44
Earnings
Revenue
$370,289
EBIT
-$20.4M
EBITDA
-$19.93M
Free cash flow
-$19.04M
Per share
EPS
-$0.92
Free cash flow per share
-$0.51
Book value per share
$3.37
Revenue per share
$0.01
TBVPS
$3.49
Balance sheet
Total assets
$129.57M
Total liabilities
$4.76M
Debt
$643,000
Equity
$124.82M
Working capital
$124.09M
Liquidity
Debt to equity
0.01
Current ratio
28.71
Quick ratio
27.69
Net debt/EBITDA
0.7
Margins
EBITDA margin
-5,382.3%
Gross margin
100%
Net margin
-5,508.4%
Operating margin
-5,517.9%
Efficiency
Return on assets
-28.4%
Return on equity
-30.5%
Return on invested capital
-75.8%
Return on capital employed
-16.3%
Return on sales
-5,508%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRDF stock price

How has the Cardiff Oncology stock price performed over time
Intraday
2.04%
1 week
1.52%
1 month
-7.19%
1 year
171.19%
YTD
-55.53%
QTD
-13.61%

Financial performance

How have Cardiff Oncology's revenue and profit performed over time
Revenue
$370,289
Gross profit
$370,289
Operating income
-$20.43M
Net income
-$20.4M
Gross margin
100%
Net margin
-5,508.4%
Cardiff Oncology's revenue has increased by 48% YoY
The gross profit has increased by 48% YoY
The net income has declined by 23% year-on-year and by 6% since the previous quarter
CRDF's operating income is down by 21% year-on-year and by 7% since the previous quarter

Growth

What is Cardiff Oncology's growth rate over time

Valuation

What is Cardiff Oncology stock price valuation
P/E
N/A
P/B
2.37
P/S
802.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
773.44
Cardiff Oncology's EPS has surged by 59% YoY and by 15% QoQ
The stock's price to book (P/B) is 53% less than its last 4 quarters average of 5.0 and 32% less than its 5-year quarterly average of 3.5
The equity has declined by 2.6% since the previous quarter
Cardiff Oncology's revenue has increased by 48% YoY

Efficiency

How efficient is Cardiff Oncology business performance
The company's return on invested capital has surged by 99% YoY
Cardiff Oncology's return on equity has surged by 87% YoY and by 35% QoQ
CRDF's return on assets has surged by 78% year-on-year and by 32% since the previous quarter
Cardiff Oncology's return on sales has increased by 17% YoY but it has decreased by 4.4% QoQ

Dividends

What is CRDF's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRDF.

Financial health

How did Cardiff Oncology financials performed over time
The company's current ratio rose by 32% QoQ
The quick ratio has grown by 31% from the previous quarter
Cardiff Oncology's debt is 99% lower than its equity
The debt to equity has plunged by 96% YoY
Cardiff Oncology's debt has shrunk by 58% YoY and by 26% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.